이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Daito PharmaceuticalLtd 관리

관리 기준 확인 0/4

Daito PharmaceuticalLtd's CEO는 Yasunobu Otsuga, Aug2012 에 임명되었습니다 의 임기는 11.83 년입니다. 는 ¥ 846.01M 가치에 해당하는 회사 주식의 2.39% 직접 소유합니다. 846.01M. 경영진과 이사회의 평균 재임 기간은 각각 1.4 년과 1.4 년입니다.

주요 정보

Yasunobu Otsuga

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	11.8yrs
CEO 소유권	2.4%
경영진 평균 재임 기간	1.4yrs
이사회 평균 재임 기간	1.4yrs

최근 관리 업데이트

Recent updates

CEO

Yasunobu Otsuga (74 yo)

11.8yrs

테뉴어

Mr. Yasunobu Otsuga has been the President of Daito Pharmaceutical Co., Ltd. since August 2012 and serves as its Chief Executive Officer. Mr. Otsuga Joined Daito Pharmaceutical Co., Ltd.In March 1975. Mr....

리더십 팀

이름	위치	테뉴어	보상	소유권
Yasunobu Otsuga	CEO, President & Representative Director	11.8yrs	데이터 없음	2.39% ¥ 815.3m
Hiroshi Matsumori	VP of Business Strategy & Head of Administrative Division and Director	1.4yrs	데이터 없음	0.085% ¥ 29.0m
Kazushige Hizume	Senior Corporate Officer	no data	데이터 없음	0.13% ¥ 42.8m
Masuo Nomura	Director	no data	데이터 없음	0.0072% ¥ 2.5m
Hiroshi Kubota	Senior Corp. Officer	1.4yrs	데이터 없음	데이터 없음
Yutaka Kuwashima	Senior Corporate Officer	no data	데이터 없음	데이터 없음
Masahiro Harai	Executive Officer	no data	데이터 없음	데이터 없음
Yoji Nakamura	Executive Officer and Deputy Head of Quality & Regulatory Affairs Division	no data	데이터 없음	데이터 없음
Yoshinori Nakajima	Executive Officer	no data	데이터 없음	데이터 없음
Eiichi Takata	Executive Officer and Head of Research & Development Division	no data	데이터 없음	데이터 없음
Toru Ishida	Executive Officer	no data	데이터 없음	데이터 없음
Masahiko Mouri	Executive Officer	no data	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 관리: 4577 의 관리팀은 경험 (평균 재직 기간 1.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yasunobu Otsuga	CEO, President & Representative Director	16.8yrs	데이터 없음	2.39% ¥ 815.3m
Hiroshi Matsumori	VP of Business Strategy & Head of Administrative Division and Director	1.4yrs	데이터 없음	0.085% ¥ 29.0m
Kazushige Hizume	Senior Corporate Officer	no data	데이터 없음	0.13% ¥ 42.8m
Masuo Nomura	Director	less than a year	데이터 없음	0.0072% ¥ 2.5m
Hitoshi Hori	Independent External Director	no data	데이터 없음	0.11% ¥ 36.7m
Ichizo Yamamoto	Independent External Director	no data	데이터 없음	데이터 없음
Atsushi Saino	Independent Outside Director	no data	데이터 없음	데이터 없음
Kimiko Komatsu	Independent Outside Director	no data	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: 4577 의 이사회는 경험(평균 재직 기간 1.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Daito PharmaceuticalLtd 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2023

Less than half of directors are independent

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 24, 2022

Less than half of directors are independent

Recent updates

New major risk - Revenue and earnings growth

Upcoming dividend of JP¥30.00 per share

Third quarter 2024 earnings released: EPS: JP¥50.14 (vs JP¥56.83 in 3Q 2023)

Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 350,000 shares, representing 2.23% for ¥1,000 million.

Price target increased by 8.6% to JP¥3,155

Daito Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Apr 12, 2024

Second quarter 2024 earnings released: EPS: JP¥50.40 (vs JP¥51.58 in 2Q 2023)

Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 160,000 shares, representing 1.01% for ¥303.36 million.

Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 160,000 shares, representing 1.01% for ¥303.36 million.

Daito Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Jan 12, 2024

Upcoming dividend of JP¥30.00 per share at 2.8% yield

First quarter 2024 earnings released: EPS: JP¥47.54 (vs JP¥59.74 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Daito Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Oct 12, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2023

Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Jul 14, 2023

Upcoming dividend of JP¥30.00 per share at 2.4% yield

Third quarter 2023 earnings released: EPS: JP¥62.51 (vs JP¥85.94 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥56.74 (vs JP¥69.11 in 2Q 2022)

Now 21% undervalued after recent price drop

Daito Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Jan 13, 2023

Upcoming dividend of JP¥30.00 per share

Less than half of directors are independent

First quarter 2023 earnings released: EPS: JP¥65.71 (vs JP¥133 in 1Q 2022)

Daito Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Oct 13, 2022

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 24, 2022

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2022 Results on Jul 14, 2022

Now 21% undervalued after recent price drop

Upcoming dividend of JP¥35.00 per share

Price target decreased to JP¥4,800

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Daito Pharmaceutical Co.,Ltd. to Report Q3, 2022 Results on Apr 14, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥25.00 per share

Price target decreased to JP¥5,100

First quarter 2022 earnings released: EPS JP¥133 (vs JP¥98.06 in 1Q 2021)

Daito Pharmaceutical Co.,Ltd. announced that it expects to receive ¥13.351 million in funding from Daiwa Securities Co., Ltd., Investment Arm

Full year 2021 earnings released: EPS JP¥311 (vs JP¥310 in FY 2020)

Upcoming dividend of JP¥23.00 per share

Third quarter 2021 earnings released

Daito Pharmaceutical Co.,Ltd. to Report Q3, 2021 Results on Apr 14, 2021

New 90-day low: JP¥3,485

New 90-day low: JP¥3,500

Revenue and earnings beat expectations

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS JP¥80.36

Daito Pharmaceutical Co.,Ltd. to Report Q2, 2021 Results on Jan 14, 2021

Daito Pharmaceutical Co.,Ltd. to Report Q1, 2021 Results on Oct 13, 2020

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령